Risk Factors and Outcomes of Gastrointestinal Bleeding in Left Ventricular Assist Device Recipients

Published:November 05, 2015DOI:
      Increasing use of left ventricular assist devices (LVADs) has been accompanied by rising incidence of gastrointestinal bleeding (GIB). Objectives of this study were to determine the yearly incidence of GIB in LVAD recipients, compare outcomes of continuous-flow (CF) and pulsatile-flow LVAD eras, and investigate for risk factors. The Healthcare Cost and Utilization Project–Nationwide Inpatient Sample database from 2005 to 2010 was analyzed. Primary outcome of interest was incidence of GIB in LVAD recipients. Multivariate logistic regression model was used to examine independent associations of GIB with risk factors and outcomes. An estimated 8,879 LVAD index admissions and 8,722 readmissions in LVAD recipients over 6 years were analyzed. The yearly incidence of GIB after LVAD implantation increased from 5% in 2005 to 10% in 2010. On multivariate regression analysis, the odds of GIB was 3.24 times greater (95% confidence interval 1.53 to 6.89) in the era of CF LVADs than in the era of pulsatile-flow LVADs. Compared to their younger counterparts, in LVAD recipients aged >65 years, the adjusted odds of GIB was 20.5 times greater (95% confidence interval 2.24 to 188). GIB did not significantly increase the inhospital mortality but increased the inpatient length of stay. In conclusion, the incidence of GIB in LVAD recipients has increased since the use of CF LVADs has increased, leading to greater inpatient lengths of stay and hospital charges. Older recipients of CF LVADs appear to be at a greater risk of GIB.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lalonde S.D.
        • Alba A.C.
        • Rigobon A.
        • Ross H.J.
        • Delgado D.H.
        • Billia F.
        • McDonald M.
        • Cusimano R.J.
        • Yau T.M.
        • Rao V.
        Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD.
        J Card Surg. 2013; 28: 604-610
        • Demirozu Z.T.
        • Radovancevic R.
        • Hochman L.F.
        • Gregoric I.D.
        • Letsou G.V.
        • Kar B.
        • Bogaev R.C.
        • Frazier O.H.
        Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device.
        J Heart Lung Transplant. 2011; 30: 849-853
        • Morgan J.A.
        • Paone G.
        • Nemeh H.W.
        • Henry S.E.
        • Patel R.
        • Vavra J.
        • Williams C.T.
        • Lanfear D.E.
        • Tita C.
        • Brewer R.J.
        Gastrointestinal bleeding with the HeartMate II left ventricular assist device.
        J Heart Lung Transplant. 2012; 31: 715-718
        • Toda K.
        • Sawa Y.
        Clinical management for complications related to implantable LVAD use.
        Gen Thorac Cardiovasc Surg. 2015; 63: 1-7
        • Aggarwal A.
        • Pant R.
        • Kumar S.
        • Sharma P.
        • Gallagher C.
        • Tatooles A.J.
        • Pappas P.S.
        • Bhat G.
        Incidence and management of gastrointestinal bleeding with continuous flow assist devices.
        Ann Thorac Surg. 2012; 93: 1534-1540
        • Crow S.
        • John R.
        • Boyle A.
        • Shumway S.
        • Liao K.
        • Colvin-Adams M.
        • Toninato C.
        • Missov E.
        • Pritzker M.
        • Martin C.
        • Garry D.
        • Thomas W.
        • Joyce L.
        Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices.
        J Thorac Cardiovasc Surg. 2009; 137: 208-215
      1. Thoratec Corporation. Bridge to Transplantation Study. HeartMate II® Left Ventricular Assist System (LVAS) - P060040. Available at: Accessed on March 1, 2015.

        • HCUP Nationwide Inpatient Sample (NIS)
        Healthcare Cost and Utilization Project (HCUP).
        Agency for Healthcare Research and Quality, Rockville, MD2011 (Available at:) (Accessed on January 7, 2015)
        • Singh G.
        • Albeldawi M.
        • Kalra S.S.
        • Mehta P.P.
        • Lopez R.
        • Vargo J.J.
        Features of patients with gastrointestinal bleeding after implantation of ventricular assist devices.
        Clin Gastroenterol Hepatol. 2015; 13: 107-114
        • Draper K.V.
        • Huang R.J.
        • Gerson L.B.
        GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis.
        Gastrointest Endosc. 2014; 80: 435-446
        • John R.
        • Boyle A.
        • Pagani F.
        • Miller L.
        Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices.
        J Cardiovasc Transl Res. 2009; 2: 154-158
        • Gunnlaugsson O.
        Angiodysplasia of the stomach and duodenum.
        Gastrointest Endosc. 1985; 31: 251-254
        • Stern D.R.
        • Kazam J.
        • Edwards P.
        • Maybaum S.
        • Bello R.A.
        • D'Alessandro D.A.
        • Goldstein D.J.
        Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD.
        J Card Surg. 2010; 25: 352-356
        • Zuckerman G.R.
        • Cornette G.L.
        • Clouse R.E.
        • Harter H.R.
        Upper gastrointestinal bleeding in patients with chronic renal failure.
        Ann Intern Med. 1985; 102: 588-592
        • Duray P.H.
        • Marcal Jr., J.M.
        • LiVolsi V.A.
        • Fisher R.
        • Scholhamer C.
        • Brand M.H.
        Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease.
        Hum Pathol. 1984; 15: 539-544
        • Pate G.E.
        • Mulligan A.
        An epidemiological study of Heyde's syndrome: an association between aortic stenosis and gastrointestinal bleeding.
        J Heart Valve Dis. 2004; 13: 713-716
        • Pareti F.I.
        • Lattuada A.
        • Bressi C.
        • Zanobini M.
        • Sala A.
        • Steffan A.
        • Ruggeri Z.M.
        Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis.
        Circulation. 2000; 102: 1290-1295
        • Crow S.
        • Chen D.
        • Milano C.
        • Thomas W.
        • Joyce L.
        • Piacentino 3rd, V.
        • Sharma R.
        • Wu J.
        • Arepally G.
        • Bowles D.
        • Rogers J.
        • Villamizar-Ortiz N.
        Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.
        Ann Thorac Surg. 2010; 90: 1263-1269
        • John R.
        • Lietz K.
        • Schuster M.
        • Naka Y.
        • Rao V.
        • Mancini D.M.
        • Rose E.A.
        • Smith C.R.
        • Oz M.C.
        • Edwards N.M.
        • Itescu S.
        Immunologic sensitization in recipients of left ventricular assist devices.
        J Thorac Cardiovasc Surg. 2003; 125: 578-591
        • Porter A.L.
        • Connolly T.
        • Heikes R.G.
        • Park C.Y.
        Misleading indicators: the limitations of multiple linear regression in formulation of policy recommendations.
        Policy Sci. 1981; 13: 397-418
        • Lopilato A.C.
        • Doligalski C.T.
        • Caldeira C.
        Incidence and risk factor analysis for gastrointestinal bleeding and pump thrombosis in left ventricular assist device recipients.
        Artif Organs. 2015; 39: 939-944
        • Miller L.W.
        • Guglin M.
        • Rogers J.
        Cost of ventricular assist devices: can we afford the progress?.
        Circulation. 2013; 127: 743-748